Abstract
Mutant Epidermal Growth Factor Receptor (EGFR) oncoproteins lacking most of subdomains I and II of the extracellular region, a deletion which includes most of the first of two cysteine-rich sequences, have been observed in multiple human epithelial tumors, including malignant gliomas. These EGFR oncoproteins, designated ΔEGFR or EGFRvIII, confer increased tumorigenicity in vivo and are often coexpressed with full-length EGFR in human tumors. We have expressed an ectodomain-derived, carboxyl-terminal deletion mutant of the p185neu oncogene (T691stop) in human glioblastoma cells coexpressing endogenous EGFR and activated ΔEGFR oncoproteins. The p185neu ectodomain-derived mutant forms heterodimers with ΔEGFR proteins and reduces the phosphotyrosine content and kinase activity of ΔEGFR monomers. As a consequence of T691stop neu expression and surface localization, cell proliferation in conditions of full growth and reduced serum and anchorage-independent growth in soft agar was reduced in glioblastoma cells expressing either endogenous EGFR alone or coexpressing EGFR and elevated levels of ΔEGFRs. T691stop neu mutant receptors abrogate the dramatic growth advantage conferred by ΔEGFR in vivo, suggesting that physical associations primarily between subdomains III and IV of the p185neu and EGFR ectodomains are sufficient to modulate signaling from activated EGFR complexes. Receptor-based inhibitory strategies exploit the thermodynamic preference for erbB ectodomains to heterodimerize, thereby creating erbB receptor assemblies which are defective in signaling and do not internalize. Pharmaceuticals which mimic the p185neu ectodomain may therefore have important therapeutic applications in advanced human malignancies expressing erbB receptors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Rourke, D., Nute, E., Davis, J. et al. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene 16, 1197–1207 (1998). https://doi.org/10.1038/sj.onc.1201635
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1201635
Keywords
This article is cited by
-
EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins
Oncogene (2006)
-
Effect and mechanism of epidermal growth factor on proliferation of GL15 gliomas cell line
Journal of Huazhong University of Science and Technology (2006)
-
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
British Journal of Cancer (2005)
-
The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR
Oncogene (2004)
-
EGFRvIII-mediated radioresistance through a strong cytoprotective response
Oncogene (2003)